Skip to main content

CORRECTION article

Front. Pharmacol., 07 July 2023
Sec. Gastrointestinal and Hepatic Pharmacology

Corrigendum: Metabonomic analysis of the anti-hepatic fibrosis effect of Ganlong capsules

ChangLing Lv,ChangLing Lv1,2YinRui LiYinRui Li3Ling Ou,Ling Ou1,2Jie Zhou,Jie Zhou1,2Fang Peng,Fang Peng1,2DingYu Wu,
DingYu Wu1,2*
  • 1College of Pharmacy, Dali University, Dali, China
  • 2Yunnan Provincial Key Laboratory of Entomological Biopharmaceutical R&D, Dali, China
  • 3Department of Pharmacy, Mengzi People’s Hospital, Mengzi, China

A Corrigendum on
Metabonomic analysis of the anti-hepatic fibrosis effect of Ganlong capsules

by Lv C, Li Y, Ou L, Zhou J, Peng F and Wu D (2023). Front. Pharmacol. 14:1122118. doi: 10.3389/fphar.2023.1122118

In the published article, there was an error in Figures 3, 6, 9 as published. The reason for this is a mistake was made in the order of BPC pictures of different tissue samples. The corrected Figures 3, 6 and 9 and their captions appear below.

FIGURE 3
www.frontiersin.org

FIGURE 3. Representative BPC of rat liver tissue in positive and negative ion mode for each group.

FIGURE 6
www.frontiersin.org

FIGURE 6. Representative BPC of rat Serum in positive and negative ion mode for each group.

FIGURE 9
www.frontiersin.org

FIGURE 9. Representative BPC graph of rat urine in positive and negative ion mode for each group.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: Ganlong capsule, hepatic fibrosis, CCl4, metabolomic analysis, LC-MS

Citation: Lv C, Li Y, Ou L, Zhou J, Peng F and Wu D (2023) Corrigendum: Metabonomic analysis of the anti-hepatic fibrosis effect of Ganlong capsules. Front. Pharmacol. 14:1231544. doi: 10.3389/fphar.2023.1231544

Received: 30 May 2023; Accepted: 04 July 2023;
Published: 07 July 2023.

Edited and reviewed by:

Shikai Yan, Shanghai Jiao Tong University, China

Copyright © 2023 Lv, Li, Ou, Zhou, Peng and Wu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: DingYu Wu, fetoio@sina.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.